ProfesionalUdic4

We started a phase II / III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage Alzheimer’s disease. It involves a change in the therapeutic target hitherto chosen: the amyloid protein

Compartir:
CategoryAlzeimer, Alzeimer

© 2022–2026 - UDIC - Unitat d'Investigació Clínica, SL · Soporte técnico